Arcutis Biotherapeutics(ARQT) - 2025 Q4 - Annual Results

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Westlake Village, CA, February 25, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2025, and provided a business update. "In 2025, Arcutis continued its strong performance trend, with more than 90% year-over-year growt ...